Paying users zone. Data is covered by .

  • Get to Allergan PLC for $13.99, or

  • get to whole website for at least 3 months from $49.99.

 

$13.99


Free Cash Flow to The Firm (FCFF)

Allergan PLC, FCFF calculation

USD $ in thousands

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net income (loss) attributable to shareholders
(Income) loss attributable to noncontrolling interest
Net noncash charges
Changes in assets and liabilities, net of effects of acquisitions
Net cash provided by operating activities
Cash paid during the year for interest, net of tax1
Additions to property, plant and equipment
Additions to product rights and other intangibles
Proceeds from sales of property, plant and equipment
Free cash flow to the firm (FCFF)
Item Description The company
FCFF Free cash flow to the firm is the cash flow available to the Allergan PLC's suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. Allergan PLC's FCFF declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.

Top


Interest Paid, Net of Tax

Allergan PLC, interest paid, net of tax calculation

USD $ in thousands

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Effective Income Tax Rate (EITR)
EITR1 % % % % %
Interest Paid, Net of Tax
Cash paid during the year for interest, before tax
Less: Cash paid during the year for interest, tax2
Cash paid during the year for interest, net of tax

2017 Calculations

2 Cash paid during the year for interest, tax = Cash paid during the year for interest × EITR
= × % =

Top


Enterprise Value to FCFF Ratio, Current

Allergan PLC, current EV/FCFF calculation, comparison to benchmarks

 
Selected Financial Data (USD $ in thousands)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals & Biotechnology
EV/FCFF, Industry
Health Care

If company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.

Otherwise, if company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.

Top


Enterprise Value to FCFF Ratio, Historical

Allergan PLC, historical EV/FCFF calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals & Biotechnology
EV/FCFF, Industry
Health Care

2017 Calculations

3 EV/FCFF = EV ÷ FCFF
= ÷ =

Ratio Description The company
EV/FCFF Enterprise value to free cash flow to the firm is whole company valuation indicator. Allergan PLC's EV/FCFF ratio increased from 2015 to 2016 but then declined significantly from 2016 to 2017.

Top